-
Most Recent
Healthcare Stocks
Healthcare encompasses a wide range of organized services to prevent, treat, and diagnose medical needs and mental illnesses. The $336 billion market is expected to grow at a compound annual growth rate of 8% until 2030, demonstrating the necessity of adequate healthcare. Healthcare companies, ranging from retailer CVS to insurance giant UnitedHealth, provide these services to a massive customer base.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
7 Dependable Dividend Stocks for Long-Term Income
Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets.
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth.
Other industries you might be interested in
Recent Healthcare Stocks Articles
Shortage of Cancer Drugs Jeopardizes Development of New Treatments
Existing products often are used in new drugs' clinical trials, meaning a cramp in supply can result in delays of even years for new treatments.
The Sweet Taste of Swiss Pharma
Drug-maker Roche Holding Ltd. (RHHBY) could win big from the Swiss franc's pegging to the euro.
Express Scripts-Medco Merger Still Looks Like a Go
Consumer groups and Big Pharma don’t like it, but the FTC still is likely to OK the Medco-Express Scripts merger.
Regeneron Shares Get a Spark
A decision by the VA has lifted prospects for the company's key drug -- and its stock.
Boston Scientific CEO Takes a Seat on the Bench
The struggling biotech company decides to wait a year for its new CEO.
Go Long Humana at $80
A close above this level would be a solid place to enter a long-side trade in Humana Inc.
Allscripts Bought Its Way Into Trouble
MDRX paid too much to acquire Eclipsys, and the all-stock deal it made will come back to haunt it.
Give Bristol-Myers the Benefit Over Merck
Bristol-Myers’ robust new drug portfolio could make it an acquisition target -- and an investing target for you -- but neither stock is a bargain.
New CEO Tasked with Getting Hospira Back on Track
Priorities for Hospira's new CEO include fixing manufacturing problems, launching biosimilars in the U.S.
Fair or Not, Patent Overhaul Bill Looks Like a Win for Big Pharma
'First-inventor-to-file' system is a victory for Big Pharma and its investors, but a crushing blow to small companies.
Glaxo Alters R&D Process to Ensure Survival in Changing Pharma Industry
GSK has created a "dragon" culture in its R&D process. Here's what it is and why analysts like the Glaxo approach.
AstraZeneca Rolls the Dice on Cholesterol Drug and Comes Up Short
Once the patent for Pfizer's popular Lipitor runs out, cheap knockoffs could start eating away at Crestor sales
Tiny Amarin Banking on Fish Oil Drug Success
The stock's upside is potentially huge if this drug takes off.
Big Pharma Eyes Rare-Disease Revenue Stream
Large drug firms are starting to look beyond common maladies to keep the cash coming.
Johnson & Johnson a Safe Play for Income
JNJ's financials are solid, and the company is making strides toward getting 11 new drugs approved by the end of 2015.
What Ails UnitedHealth
Share repurchases, meager dividends, low margins and pending regulations cloud prospects for UnitedHealth Group's stock.
Vertex Scores Big With Hepatitis Drug
The company's new hepatitis C medication, Incivek, is outselling Merck's drug by 4-to-1. What's more, it's close to adding another drug to its arsenal.
A Rare Pick for an Overbought Market
For most stocks, this is not the time to go long, but Coventry Health Care (NYSE:CVH) may be an exception.
